MAX and prostate carcinoma: The increased active nuclear beta-catenin through interaction with MYC/MAX transcription factor functions as a co-repressor of PrKD1 expression and thereby perpetuates the down regulation of PrKD1 in advanced prostate cancer (Figure 6).